Enhanced Human Growth Hormone Receptor Antagonist Compositions and Methods for Cancer Treatment

Improved compositions and methods for treating cancer using human growth hormone receptor antagonists with enhanced efficacy, safety, and pharmacokinetics.

The original patent disclosed a combination therapy for treating cancer using human growth hormone receptor antagonists. However, the existing patent has limitations in terms of efficacy, safety, and pharmacokinetics. The new inventive concept addresses these limitations by introducing modified antagonists with improved properties.

The new inventive concept comprises modified human growth hormone receptor antagonists conjugated to polyethylene glycol molecules with branched structures, enhancing their pharmacokinetics and reducing immunogenicity. The antagonists can be formulated with pH-sensitive polymers to improve bioavailability and stability. The compositions can be administered in combination with chemotherapeutic drugs to enhance their efficacy and reduce toxicity. The kit for treating cancer includes a composition with instructions for administration.

The new claims introduce the use of branched polyethylene glycol molecules, pH-sensitive polymers, and modified antagonists with improved pharmacokinetics and reduced immunogenicity, which are not disclosed in the original patent. These modifications provide a significant improvement over the existing technology.

Alternative embodiments include using different types of polymers, varying the molecular weight of the polyethylene glycol molecule, and modifying the antagonist to target specific cancer types. Variations of the kit may include different formulations and administration routes.

The enhanced human growth hormone receptor antagonist compositions and methods have significant commercial potential in the cancer treatment market, particularly in the areas of breast cancer, central nervous system cancer, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cancer, and pancreatic cancer.